Earnings Summary

Freeline Therapeutics Holdings plc’s revenue jumped +Inf% since last year same period to $0.01Mn in the Q3 2023. On a quarterly growth basis, Freeline Therapeutics Holdings plc has generated -99.19% fall in its revenue since last 3-months.

Freeline Therapeutics Holdings plc’s net profit jumped 18.83% since last year same period to $-12.09Mn in the Q3 2023. On a quarterly growth basis, Freeline Therapeutics Holdings plc has generated 24.5% jump in its net profits since last 3-months.

Freeline Therapeutics Holdings plc’s net profit margin jumped NaN% since last year same period to -241760% in the Q3 2023. On a quarterly growth basis, Freeline Therapeutics Holdings plc has generated -9216.46% fall in its net profit margins since last 3-months.

Freeline Therapeutics Holdings plc’s earning per share (EPS) estimates for the current quarter stand at -0.23 - a 0% jump from last quarter’s estimates.

Freeline Therapeutics Holdings plc’s earning per share (EPS) estimates for the current year stand at -0.23.

Freeline Therapeutics Holdings plc’s earning per share (EPS) fell -1278.85% since last year same period to -2.76 in the Q3 2023. This indicates that the Freeline Therapeutics Holdings plc has generated -1278.85% annual rate of fall in its earning per share (EPS) in the last 4 quarters.